Psychedelics: federal and state overview

Federal scheduling first. State programs (e.g. Oregon psilocybin, Colorado natural medicine) are not yet sourced.

Tier tags: L1 statute/ordinance, L2 final or temporary rule, L3 official guidance or agency action, L4 pending bill or proposed rule, L5 news or lead (never law).

Federal

[L2] Federal: Schedule I scope. Quoted: "Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it." Source: 21 CFR 1308.11(a) (eCFR, as of 2026-10-01)
[L2] Federal: Psilocybin and psilocyn listed in Schedule I (hallucinogenic substances). Quoted: "Psilocybin 7437 (30) Psilocyn 7438" Source: 21 CFR 1308.11(d) (eCFR, as of 2026-10-01)

States

Official text (batch 7)

[L1] Oregon: Supervised psilocybin administration sessions. Quoted: "475A.220 Definitions for ORS 475A.210 to 475A.722. As used in ORS 475A.210 to 475A.722: (1) Administration session means a session at which a client consumes and experiences the effects of a psilocybin product under the supervision of a psilocybin service facilitator." Source: ORS 475A.220 (Oregon Psilocybin Services Act)
[L1] Colorado: Natural medicine = psilocybin/psilocyn; DMT optional. Quoted: ""Natural medicine" means the following substances: (I) Psilocybin; or (II) Psilocyn. (b) In addition to the substances listed in subsection (12)(a) of this section, "natural medicine" includes: (I) Dimethyltryptamine, if recommended by the board and approved by the director and the executive director of the state licensing authority for inclusion on or after June 1, 2026;" Source: C.R.S. 12-170-104(12) (Natural Medicine Health Act; 2023 edition PDF, later amendments UNVERIFIED)
[L1] New Mexico: Medical psilocybin: qualified patient and conditions. Quoted: ""qualified patient" means a patient whose 20 clinician has judged the patient to be a medically 21 appropriate candidate for the use of medical psilocybin based 22 on being diagnosed with a qualifying condition; 23 I. "qualifying condition" includes: 24 (1) major treatment-resistant depression; 25 (2) posttraumatic stress disorder; SJC/SB 219 Page 2 1 (3) substance use disorders; 2 (4) end-of-life care;" Source: N.M. SB 219 (2025), Medical Psilocybin Act, final passed text (chapter cite UNVERIFIED here)

Official text (batch 9)

[L1] Colorado: SB23-290 effective July 1, 2023. Quoted: "SECTION 45. Effective date. This act takes effect July 1, 2023, and applies to offenses committed on or after July 1, 2023." Source: Colo. SB23-290 (signed act), § 45
[L1] Colorado: Natural medicine article sunsets Sept. 1, 2032. Quoted: "THIS ARTICLE 170 IS REPEALED, EFFECTIVE SEPTEMBER 1,2032." Source: Colo. SB23-290 (signed act), repeal of Article 170
[L3] New Mexico: SB 219 effective June 20, 2025 per NMDOH. Quoted: "signed Senate Bill 219 , known as the Medical Psilocybin Act, into law. This will take effect on June 20, 2025." Source: NMDOH Medical Psilocybin Program page (agency; the effective date is not stated in the enrolled SB 219 text we read)

Thynk Industries, DBA Zero Human Thynk — The nation's premier cannabis, hemp, kratom, psychedelics, peptides & nicotine compliance experts since 2009. Trial policy wiki; not legal advice.

Authority tiers: L1 statute, L2 final/temporary rule, L3 official guidance, L4 pending bill/proposed rule, L5 news/lead/commentary (never law). Sources checked: 2026-10-30.